-

Market Insights Reports

Since the approval of Orthoclone OKT3, a murine monoclonal antibody against T cell expressed CD3 (for the treatment of acute transplant rejection) in 1986, antibody therapeutics have evolved into a prominent class of therapeutics. These therapeutics have high target specificities and favorable safety profiles. Currently, close to 100 monoclonal antibodies have been approved while more than 500 molecules are being evaluated in clinical trials. Some of the recently approved monoclonal antibody the

...read more

Exosomes are extracellular vesicles that play an important role in cell-to-cell communication and act as carriers of circulating nucleic acids, lipids and proteins in body. Over time, various research studies have demonstrated the potential of exosomes in disease diagnosis and drug delivery applications, owing to their ability to act as biomarkers for various diseases and transport important functional elements. Given the various benefits, exosomes have gained significant interest in the biophar

...read more

First introduced in 1950s, the flow cytometry technique has gained significant attention in the past few decades. This can be attributed to the fact that flow cytometry has been demonstrated to be capable of overcoming various challenges associated with conventional analytical techniques, such as western blotting and immunohistochemistry. The key concerns related to traditional approaches include low specificity and sensitivity, time and cost intensive procedures, higher chances of producing fal

...read more

Given the advancement of several promising microbiome-based live biotherapeutic products through clinical pipeline, this upcoming therapeutic segment is anticipated to become one of the fastest growing markets within the pharmaceutical industry in the coming years. Specifically, in 2020, around 575 IND applications were filed for such therapies, targeting a myriad of diseases indications, including autoimmune, gastrointestinal, infectious, metabolic and oncological disorders, indicating remarkab

...read more

Over the past few years, the prevalence of neurological disorders has increased at an annualized rate of 10.9%. Further, the mortality associated with such diseases is projected to account for 12.2% of the global death rate, in 2030. In this context, several research initiatives are underway to identify an approach that allows effective delivery of the target medication directly into the brain. One key challenge currently faced by researchers is the presence of the complex blood brain barrier (B

...read more

Cancer is one of the leading causes of death, worldwide. In 2020 alone, over 19 million new cases of the disease (affecting different organs) and close 10 million associated fatalities, were reported worldwide. Over the next couple of decades, experts believe that the global cancer burden is likely to increase by almost 50%. Currently, a variety of therapeutic measures are available for the treatment of different types of cancers; of these, surgery, chemotherapy, and radiation therapy, are consi

...read more

The global healthcare sector has been overtly reluctant to embrace technology. This may partially be due to the failure of early digitization efforts, which were fraught with challenges and turned out to be more of a liability rather than a path forward. In fact, according to a study, clinicians ended up spending more than twice as much time on administrative work (49%), such as updating electronic medical records, than on seeing patients (27%). The delivery of modern healthcare services is, the

...read more

Since the approval of the first protein / peptide-based therapy (recombinant human insulin) in 1982, there has been a substantial increase in the R&D initiatives focused on such products. Earlier, majority of the biologics were administered subcutaneously. However, with the technological advancements in delivery formulations, oral delivery of therapeutic interventions   has gained significant traction, prompting stakeholders to leverage their expertise in the development of orally admin

...read more

Over the years, the popularity of biologics has led to an evident shift in the focus of pharmaceutical companies, from traditional interventions towards more complex and advanced pharmacological interventions, such as peptide therapeutics. Since the discovery of insulin, the peptide therapeutics market has evolved significantly. Presently, over 80 peptide-based drugs are available in the market for the treatment of an array of diseases, including cancer, chronic pain, diabetes, HIV infection, mu

...read more

Over the years, the rising popularity of biologics has led to a paradigm shift in the healthcare industry. In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines and gene therapies), by the US FDA, have steadily risen. In fact, over 8,000 biological pharmaceutical products are currently under clinical investigation worldwide. Given the evident benefits of biologics over small molecule drugs (including high e

...read more

Packaging is considered a critical aspect of pharmaceutical manufacturing. It is, therefore, imperative for drug manufacturers to ensure that formulations enclosed in primary containers are safe for consumption / administration. Despite being well established, there are several concerns associated with the drug packaging process, such as the risk of contamination, filling errors (inaccurate dose dispensation), complex packaging systems, integrity related concerns (pores, cracks and scratches) of

...read more

It is a well-known fact that clinical trials form an integral part of the overall drug development process, enabling innovators to assess safety and efficacy of their drug candidates / devices. These studies account for around 50% of the total time and capital invested in the development process. However, the conduct of trials is often fraught with several challenges, including scientific and operational complexity, concerns associated with recruitment and retention of suitable patients, issues

...read more

Isolation of the first site-specific restriction enzyme, Hind II, in the 1970s, became one of the breakthrough advances in biotechnology. This led to the discovery of various methods for manipulating living creatures at the genomic level, thereby, opening up a slew of new possibilities in basic and applied life sciences domain. Soon after, in the 1980s, the US FDA authorized human insulin, marketed under the brand name HUMULIN®, as the world's first genetically modified medication. With

...read more

Various studies have indicated that the genetic composition of two individuals is unlikely to be similar. This can be attributed to the fact that the genetic makeup of an individual is influenced by various factors, such as family history, as well as environmental and health conditions. Therefore, one treatment cannot be expected to be successful in every patient suffering from the same disorder. It is worth highlighting that the inability to report a health issue to a medical practitioner in it

...read more

With several blockbuster drugs in the market and numerous others in the development pipeline, the modern biopharmaceutical industry is poised to grow at a significant pace over the coming years. The success of biopharmaceutical drugs has necessitated an upgrade of conventional biologics manufacturing equipment. As a result, the domain has witnessed several technological advancements, including the adoption of controllers and automated systems. Sensors and controllers are the essential elements o

...read more

Targeted therapeutics is fast emerging as the key focus area in biopharmaceutical industry. Oral targeted therapeutics has attracted many drug developers due to the ease of administration it offers to patients (especially pediatric and geriatric patients). In the case of leukemia, current marketed oral drugs include Gleevec, Tasigna, Sprycel, Bosulif, Imbruvica and Iclusig. Scope of the Report The ‘Oral Oncolytics Series: Leukemia, 2014 - 2024’ report provides an exte

...read more

The field of genomic data collection and analysis has evolved significantly since the introduction of a gene sequencing method by Frederick Sanger in 1977. Advances in DNA sequencing technologies have led to significant developments in a variety of healthcare-focused research fields, such as precision medicine and diagnostics. Particularly, the impact of next generation sequencing (NGS) methods, enabling whole genome and whole exome sequencing, has been the most profound. This high throughput, p

...read more

Over the past few years, there has been an evident growth in the pipeline of cell-based products, fueled by the demand for effective therapeutics. However, such products are often temperature sensitive, requiring freezing / cryogenic conditions for transport and storage. In fact, as per a study conducted by the USFDA, across more than 80% submissions for mesenchymal cell-based therapies, it was reported that such products required cryopreservation. Therefore, there is a need to identify preserva

...read more
  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry